Stella Pharma (TSE:4888) Beneish M-Score: -4.22 (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4888 Stella Pharma Corp TSE:4888
74 GF Score
Price 円325.00
GF Value 円337.87
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Stella Pharma Beneish M-Score?

Stella Pharma TSE:4888 -0.31% 74 Beneish M-Score is -4.22 as of Jul. 15, 2026. GuruFocus rates TSE:4888 with a GF Score™ of 74/100 and a GF Value™ of 円337.87 (Fairly Valued). The stock has 4 warning signs investors should review. Among 824 Biotechnology companies, Stella Pharma ranks better than 90.78% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -4.22 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Stella Pharma's Beneish M-Score or its related term are showing as below:

TSE:4888' s Beneish M-Score Range Over the Past 10 Years
Min: -4.22   Med: -2.35   Max: 1.02
Current: -4.22

During the past 8 years, the highest Beneish M-Score of Stella Pharma was 1.02. The lowest was -4.22. And the median was -2.35.


Stella Pharma Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Stella Pharma's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Stella Pharma Beneish M-Score Chart

Stella Pharma Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beneish M-Score
Get a 7-Day Free Trial -2.66 -0.81 -2.35 1.02 -4.22

Stella Pharma Semi-Annual Data
Mar19 Mar20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.35 0.00 1.02 0.00 -4.22

TSE:4888 vs VRTX, REGN, ALNY: Beneish M-Score Comparison

For the Biotechnology subindustry, Stella Pharma's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Stella Pharma Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Stella Pharma's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Stella Pharma's Beneish M-Score falls into.


TSE:4888
74GF Score
Stella Pharma Corp TSE:4888
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Stella Pharma Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Stella Pharma for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.2818+0.528 * 1.0195+0.404 * 0.9748+0.892 * 0.3365+0.115 * 0.9077
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1+4.679 * -0.099495-0.327 * 1.0259
=-4.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was 円67.8 Mil.
Revenue was 円323.4 Mil.
Gross Profit was 円279.2 Mil.
Total Current Assets was 円4,353.1 Mil.
Total Assets was 円4,486.7 Mil.
Property, Plant and Equipment(Net PPE) was 円47.1 Mil.
Depreciation, Depletion and Amortization(DDA) was 円28.6 Mil.
Selling, General, & Admin. Expense(SGA) was 円0.0 Mil.
Total Current Liabilities was 円260.0 Mil.
Long-Term Debt & Capital Lease Obligation was 円588.5 Mil.
Net Income was 円-780.9 Mil.
Gross Profit was 円0.0 Mil.
Cash Flow from Operations was 円-334.5 Mil.
Total Receivables was 円714.7 Mil.
Revenue was 円961.1 Mil.
Gross Profit was 円845.7 Mil.
Total Current Assets was 円5,243.5 Mil.
Total Assets was 円5,417.1 Mil.
Property, Plant and Equipment(Net PPE) was 円66.5 Mil.
Depreciation, Depletion and Amortization(DDA) was 円34.7 Mil.
Selling, General, & Admin. Expense(SGA) was 円0.0 Mil.
Total Current Liabilities was 円390.4 Mil.
Long-Term Debt & Capital Lease Obligation was 円608.1 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(67.757 / 323.389) / (714.666 / 961.058)
=0.209522 / 0.743624
=0.2818

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(845.748 / 961.058) / (279.156 / 323.389)
=0.880018 / 0.86322
=1.0195

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (4353.125 + 47.096) / 4486.694) / (1 - (5243.479 + 66.52) / 5417.104)
=0.019273 / 0.019772
=0.9748

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=323.389 / 961.058
=0.3365

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(34.723 / (34.723 + 66.52)) / (28.6 / (28.6 + 47.096))
=0.342967 / 0.377827
=0.9077

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(0 / 323.389) / (0 / 961.058)
=0 / 0
=1

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((588.5 + 259.96) / 4486.694) / ((608.14 + 390.444) / 5417.104)
=0.189106 / 0.184339
=1.0259

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-780.917 - 0 - -334.514) / 4486.694
=-0.099495

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Stella Pharma has a M-score of -4.22 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -4.22 mean?
Stella Pharma (TSE:4888) has a Beneish M-Score of -4.22 as of Jul. 15, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Stella Pharma and its competitors. According to the industry distribution chart, Stella Pharma ranks #76 out of 824 companies in the Biotechnology industry, placing it in the top 9.2%.
Is Stella Pharma's Beneish M-Score too high?
Stella Pharma's current Beneish M-Score is -4.22. Based on the distribution chart, Stella Pharma ranks #76 out of 824 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Stella Pharma has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Stella Pharma's Beneish M-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Stella Pharma ranks #76 out of 824 companies for Beneish M-Score. This places Stella Pharma in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Stella Pharma and its competitors. Stella Pharma's current Beneish M-Score is -4.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stella Pharma stock overvalued right now?
Based on GuruFocus' analysis, Stella Pharma (TSE:4888) is currently considered Fairly Valued. The stock's GF Value™ is 円337.87, compared to a current price of 円325.00 — trading 3.8% below its estimated fair value. The current Beneish M-Score is -4.22. Stella Pharma's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Stella Pharma (TSE:4888), the current Beneish M-Score is -4.22 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Stella Pharma (TSE:4888) Overvalued in 2026?

Based on GuruFocus' analysis, Stella Pharma stock appears to be undervalued. The current stock price of 円325.00 is trading 3.8% below its estimated GF Value™ of 円337.87. GuruFocus considers Stella Pharma to be Fairly Valued.

Key valuation signals for TSE:4888:

  • Beneish M-Score: -4.22
  • GF Value™: 円337.87 vs. price of 円325.00 (3.8% below fair value)
  • GF Score™: 74/100 with 4 warning signs

No single metric tells the full story. See the TSE:4888 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Stella Pharma Business Description

Address 3-2-7 Korai-bashi, Chuo-ku, Osaka Prefecture, Osaka, JPN, 541-0043
Stella Pharma Corp is a therapeutic drug research and development company. It is focused on the development of boron compounds, particularly used in boron neutron capture therapy (BNCT). The BNCT is a form of cancer radiation therapy for destroying cancer cells.
74GF Score

Get the complete analysis for TSE:4888

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円325.00
Price
円337.87
GF Value